PolymarketKapalıKullanılabilirliği kontrol etKYC yok%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreBu piyasa sonuçlandı: No
Sonuçlandı: 11 Haz 2026 09:52
Sağlayıcı tarafından doğrulanmış sonuç
CoinRithm bu piyasa için kazanan ve sonuçlanma zamanı konusunda sağlayıcı destekli kanıta sahip.
Kazanan Sonuç
No
7 gün kala
—
24 saat kala
8%
SürprizGüncel ima edilen olasılık
Hayır 100%+0.9pt
Piyasa kalitesi
22 / 100
Düşük kalite24s Hacim
₺44,9 B
Likidite
—
Likidite bilinmiyorAlis / Satis
- / 0.4%
Piyasa verileri
70 gün önce guncellendi
Guncelligini yitirmis4 Haz 26 19:3510 Haz 26 0:00
Olasılık Zaman Çizelgesi
Yes0%
No100%
100%
0%
Kurallar
As of market creation, the FDA's expected decision date for the specified application is June 10, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Camurus's Oclaiz as a treatment for patients with acromegaly by June 24, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
